Arginase 1 genetic variation is associated with the risk of vascular complications in type 2 diabetes.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Biomarkers in medicine Pub Date : 2025-02-01 Epub Date: 2025-01-31 DOI:10.1080/17520363.2025.2455924

X H Chen, L Li, S Y Ma, C Q Ling, J Q Lai, H J Yao, W B Guo, Y Yang, Y Zhang, W J Lin, F Z He

{"title":"Arginase 1 genetic variation is associated with the risk of vascular complications in type 2 diabetes.","authors":"X H Chen, L Li, S Y Ma, C Q Ling, J Q Lai, H J Yao, W B Guo, Y Yang, Y Zhang, W J Lin, F Z He","doi":"10.1080/17520363.2025.2455924","DOIUrl":null,"url":null,"abstract":"Objective: This study aims to explore the association between arginase 1 (ARG1) genetic variation and susceptibility to type 2 diabetes (T2DM) vascular complications, a primary cause of morbidity and mortality in diabetics.Methods: ARG1, a risk gene for cardiovascular disease, was identified from GEO datasets GSE22255 and GSE58294. The ENCODE database identified four candidate single-nucleotide polymorphism (SNP) loci. Nine hundred ninety-two T2DM patients underwent SNP genotyping, and relevant biochemical markers were tested. Logistic regression analysis calculated the odds ratio (OR) and 95% confidence interval (CI) between ARG1 SNP and diabetic vascular complications.Results: Out of 985 patients, 250 had CHD, with the TTTG group accounting for 64/250. This group showed a significant reduction in CHD risk (non-TTTG factor-adjusted OR = 1.61, 95% CI: 1.14-2.29, p = 0.008). The combination of the TTTG group, age, central obesity, and hypertension better predicted CHD risk (Area under the curve = 0.72, p < 0.001).Conclusions: ARG1 polymorphisms significantly impact vascular complications in T2DM patients, implying that ARG1 genetic variation may be a potential prevention and treatment target.Trial registration: ChiCTR1800015661.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"63-72"},"PeriodicalIF":2.1000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792801/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2455924","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aims to explore the association between arginase 1 (ARG1) genetic variation and susceptibility to type 2 diabetes (T2DM) vascular complications, a primary cause of morbidity and mortality in diabetics.

Methods: ARG1, a risk gene for cardiovascular disease, was identified from GEO datasets GSE22255 and GSE58294. The ENCODE database identified four candidate single-nucleotide polymorphism (SNP) loci. Nine hundred ninety-two T2DM patients underwent SNP genotyping, and relevant biochemical markers were tested. Logistic regression analysis calculated the odds ratio (OR) and 95% confidence interval (CI) between ARG1 SNP and diabetic vascular complications.

Results: Out of 985 patients, 250 had CHD, with the TTTG group accounting for 64/250. This group showed a significant reduction in CHD risk (non-TTTG factor-adjusted OR = 1.61, 95% CI: 1.14-2.29, p = 0.008). The combination of the TTTG group, age, central obesity, and hypertension better predicted CHD risk (Area under the curve = 0.72, p < 0.001).

Conclusions: ARG1 polymorphisms significantly impact vascular complications in T2DM patients, implying that ARG1 genetic variation may be a potential prevention and treatment target.

Trial registration: ChiCTR1800015661.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

精氨酸酶1基因变异与2型糖尿病血管并发症的风险相关。

目的：本研究旨在探讨精氨酸酶1 （ARG1）基因变异与2型糖尿病（T2DM）血管并发症易感性之间的关系。2型糖尿病是糖尿病患者发病和死亡的主要原因。方法：从GEO数据集GSE22255和GSE58294中鉴定心血管疾病危险基因ARG1。ENCODE数据库鉴定出4个候选单核苷酸多态性（SNP）位点。对992例T2DM患者进行SNP基因分型，并检测相关生化指标。Logistic回归分析计算ARG1 SNP与糖尿病血管并发症的比值比（OR）和95%可信区间（CI）。结果：985例患者中有250例发生冠心病，其中TTTG组占64/250。该组冠心病风险显著降低（非tttg因素调整OR = 1.61, 95% CI: 1.14-2.29, p = 0.008）。TTTG组、年龄、中心性肥胖和高血压联合作用能更好地预测冠心病风险（曲线下面积= 0.72,p）结论：ARG1基因多态性显著影响T2DM患者血管并发症，提示ARG1基因变异可能是潜在的防治靶点。试验注册：ChiCTR1800015661。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.